A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 411 participants.
Also called NCT04964557
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 411 participants
- Sponsor
- Registry
-
NCT04964557 -
2020-005845-18
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Denmark, Hungary, Netherlands, Poland, Slovakia, Spain
- Registry status
- Completed
Technical summary
Registry record NCT04964557. Randomized; quadruple masking; primary purpose treatment. Start 2021-07-07 (actual); primary completion 2022-07-15 (actual). Results posted on 2023-12-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
- Acronym
- SOLANO
- Condition
- Hyperlipidaemia
- Intervention (Drug)
- AZD8233
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct04964557- Content hash
d30615132a4fb9c23929a0dcb5a269a942e28e8a82b22b0d5a5a20e94e6906ff